This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merrimack Pharmaceuticals Inc (MACK)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -130.68M -91.75M -79.68M -50.16M
Operating Gains/Losses 0.00 0.00 864.00K -130.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables 3.41M -1.84M -3.68M -1.98M
(Increase) Decrease in Inventories 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets -1.81M -2.35M 0.00 0.00
(Decrease) Increase In Payables 13.30M 6.98M 3.22M -830.00K
(Decrease) Increase In Other Current Liabilities 0.00 0.00 5.60M 1.02M
(Increase) Decrease In Other Working Capital -1.88M 1.58M 13.25M 14.42M
Other Non-Cash Items 15.86M 6.38M 6.95M 8.22M
Net Cash From Continuing Operations -95.18M -79.82M -52.82M -26.37M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -95.18M -79.82M -52.82M -26.37M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 26.00K
Cash Used for Investing Activities
Sale of Short-Term Investments 0.00 0.00 0.00 0.00
Purchases of Property, Plant & Equipment -9.86M -3.19M -3.75M -5.02M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments 0.00 0.00 0.00 0.00
Other Cash from Investing Activities -59.00K -247.00K 7.00K 99.00K
Cash Provided by Financing Activities
Net Cash From Investing Activities -27.74M -75.22M -3.75M -4.90M
Issuance of Debt 121.54M 41.13M 0.00 0.00
Cash Used for Financing Activities
Issuance of Capital Stock 28.75M 105.45M 78.69M 4.46M
Repayment of Long-Term Debt 0.00 -48.00K -443.00K -864.00K
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends -3.00K -4.24M 0.00 0.00
Other Financing Charges, Net 0.00 0.00 -1.95M 0.00
Net Cash From Financing Activities 150.29M 142.30M 76.30M 3.60M
Effect of Exchange Rate Changes 0.00 0.00 0.00 0.00
Net Change in Cash & Cash Equivalents 27.37M -12.74M 19.74M -27.67M
MACK News

MACK Merrimack Pharmaceuticals Inc

Analysts Ratings for MACK

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 4 3 3 4
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET MACK ANALYST REPORT

Brokerage Partners

MACK Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs